IMD-1-0242 © 2005
Leleux, Benoit F.; Kemanian, Victoria; Pahwa, Atul; Siebenbuerger, Karin
The Novartis Venture Fund is considering investing into a start up; Genedata; and must take into consideration the valuation investigation by both the start up as well as Venture Valuation -- an independent boutique organization that specializes in valuing high growth potential startups.
Novartis Venture Fund Valuation Dilemmas Case Study Solution
NVF uses the Venture Valuation stimulation to find out how best to structure the following round of financing for Genedata and the case demands the reader assess and to discuss additional funding conditions pricing; and exit strategy for the fund.
Subjects: Valuation; Start-up; Venture Capital; Pharma; Pharmaceutical; Investment Strategy; Fund
Settings: Switzerland; Venture Capital; Pharmaceutical; $100 million; July 1999
Related Case Solutions & Analyses:
MapQuest
Donna Dubinsky and Apple Computer, Inc
Resuming Internationalization at Starbucks
Financing the Mozal Project
Fox Venture Partners
HemoShear, LLC: Series C Round Financing
International Economics, 4. Industrialization, Globalization, and Labor Markets
Dividend Policy at Fuyao Glass
Value Investing, Human Behavior – and Why You Should Ignore the Market
Perspective, Institutions and Basic Issues
